Table 4. Outcomes of RMS in similar studies from India.
| Summary of recent studies in paediatric RMS from Indiaa | |||||
|---|---|---|---|---|---|
|
Variable |
Bansal et al [13] | Dua et al [11] | Bhuvan et al [12] | Present study | |
| Localised | All RMS | ||||
| Sample size (years of accrual) | 159 (23) | 14 (6) | 70 (16) | 182 (6) | 221 (6) |
| % distribution as per risk (LR/IR/HR) | 35/56/11 | 28/50/22 | 18/52/30 | 20/80/- | 9/7/66/18 |
| % patients with nodal disease (N1) | 47% (36/76) | Not specified | 37% | 39% | 40% |
| % patients with large tumours (>5 cm) | 68% (69/101) | Not specified | 44% | 56% | 60% |
| % patients with tumours at unfavourable sites | 67% | 35%–50% | 91% | 73% | 75% |
| % patients who received RT | 66% | 86% | 55% | 94% | 95% |
| Dose of cyclophosphamide/cycle | Not specified | Not specified | 1.8gm/m2 | 2.2 gm/m2 | |
| FOXO1 fusion performed | No | No | No | Yes (140 localised RMS) | |
| EFS/OSb | 5-year EFS: 43.6% | 5-year EFS/OS: 57.1%/66.7% | 3-year EFS/OS: 25.7%/49% | 3-year EFS/OS: 58.00%/70.15% 5-year EFS/OS: 54.59%/62.61% |
3-year EFS/OS: 51.03%/61.77% 5-year EFS/OS: 48.48%/55.46% |
| Abandonment rate | 33% | 14% | 23% | 5% | |
a
only full text papers included
b
excluding abandonment